

RECENT ADVANCES IN AI-DRIVEN DRUG DESIGN AND GREEN SYNTHESIS STRATEGIES: AN INNOVATIVE REVIEW IN MODERN PHARMACEUTICAL CHEMISTRY

KONDA RAVI KUMAR

Professor, Department of Pharmacy, Hetero Institute of Pharmaceutical Sciences, Sathupally, Telangana, India

*Corresponding Author


Dr. Konda Ravi Kumar

Article History: Received: 21 Feb 2026, Revised: 11 Mar 2026, Accepted: 26 Apr 2026

Abstract: Artificial intelligence (AI) and green synthesis strategies are transforming modern pharmaceutical chemistry by improving drug discovery efficiency and reducing environmental burden. Conventional drug development is costly, time-consuming, and associated with high attrition rates. AI-driven approaches, including machine learning (ML), deep learning (DL), artificial neural networks (ANNs), and generative algorithms, have accelerated target identification, lead optimization, molecular docking, predictive toxicology, and pharmacokinetic assessment. These computational tools facilitate rapid screening of chemical compounds and improve precision in identifying promising therapeutic candidates. Simultaneously, green chemistry has emerged as an environmentally sustainable approach in pharmaceutical manufacturing by minimizing hazardous chemicals, waste generation, and energy consumption. Techniques such as microwave-assisted synthesis, ultrasound-assisted reactions, biocatalysis, solvent-free synthesis, and continuous flow chemistry have gained substantial attention in reducing ecological impact while maintaining product efficiency. The integration of AI with green synthesis strategies further enhances pharmaceutical innovation through optimized reaction pathways, predictive process modeling, and sustainable molecular design. AI-supported green chemistry enables safer chemical production and resource-efficient pharmaceutical manufacturing. Applications in oncology, infectious diseases, neurological disorders, and precision medicine demonstrate the growing impact of these technologies. Despite remarkable advancements, challenges including algorithm transparency, data quality, regulatory concerns, computational costs, and scalability remain barriers to widespread implementation. Future pharmaceutical research is expected to increasingly adopt AI-assisted sustainable synthesis models for rapid and eco-friendly therapeutic development. This review summarizes recent developments in AI-driven drug design and green synthesis approaches, emphasizing their applications, advantages, limitations, and future perspectives in modern pharmaceutical chemistry.

Keywords: Artificial intelligence; Drug design; Green synthesis; Machine learning; Pharmaceutical chemistry; Sustainable drug development.

This article is licensed under a Creative Commons Attribution-Non-commercial 4.0 International License. Copyright © 2026 Author(s) retains the copyright of this article.



I. INTRODUCTION

Modern pharmaceutical chemistry has undergone remarkable transformation with the introduction of artificial intelligence (AI) and sustainable synthetic approaches. Traditional drug discovery is often expensive, labor-intensive, and time-consuming, generally requiring more than 10–15 years with high development costs and significant clinical failure rates [1]. Therefore, advanced computational technologies and environmentally sustainable methodologies are increasingly adopted to improve efficiency and reduce limitations associated with conventional pharmaceutical development.

Artificial intelligence has emerged as a powerful tool in modern drug discovery. AI techniques such as machine learning (ML), deep learning (DL), natural language processing (NLP), and neural networks facilitate rapid data interpretation and prediction of molecular

interactions [2]. These technologies help researchers identify therapeutic targets, optimize lead compounds, predict toxicity, and improve pharmacokinetic properties. AI-assisted platforms can analyze large biological datasets and identify novel drug candidates faster than traditional experimental methods.

In parallel, green synthesis strategies have gained considerable importance due to increasing environmental concerns regarding pharmaceutical manufacturing. Conventional synthetic methods frequently involve toxic solvents, hazardous reagents, and energy-intensive procedures that contribute to environmental pollution [3]. Green chemistry principles aim to reduce waste generation, improve atom economy, minimize toxicity, and promote sustainable production processes. Methods such as biocatalysis, microwave-assisted synthesis, and solvent-

free reactions have significantly improved pharmaceutical sustainability.

The convergence of AI and green chemistry represents an emerging interdisciplinary area in pharmaceutical sciences. AI-driven optimization can predict environmentally safer synthetic routes and improve reaction efficiency while minimizing chemical waste [4]. Such integrated strategies support sustainable drug development and align with global environmental regulations.

This review summarizes recent advances in AI-driven drug design and green synthesis strategies in pharmaceutical chemistry, highlighting emerging technologies, applications, challenges, and future opportunities.

2. AI IN MODERN DRUG DISCOVERY

Artificial intelligence has significantly improved the drug discovery process by enabling faster and more accurate prediction of therapeutic compounds. Traditional drug development generally involves random screening approaches, resulting in low success rates and increased expenditure [5]. AI has addressed these challenges through predictive computational modeling and automated data analysis.

AI applications in drug discovery include target identification, lead optimization, molecular modeling, virtual screening, toxicity prediction, and drug repurposing. Machine learning algorithms analyze large chemical and biological databases to recognize molecular patterns associated with therapeutic efficacy [6].




Figure 01: illustrates the general workflow of AI-driven drug discovery in pharmaceutical chemistry.

AI-based computational systems reduce the time required for identifying candidate molecules. During the COVID-19 pandemic, AI-assisted platforms accelerated antiviral candidate screening and vaccine-related therapeutic exploration [7]. Furthermore,

pharmaceutical companies increasingly adopt AI technologies for predictive modeling and precision drug design.

Table 01: Major Applications of AI in Drug Discovery

S. No	AI Application	Role in Drug Discovery
1	Target Identification	Identification of disease-associated targets
2	Virtual Screening	Rapid screening of drug molecules
3	Molecular Docking	Drug–target interaction prediction
4	ADMET Prediction	Toxicity and pharmacokinetic analysis
5	Drug Repurposing	Identification of alternative therapeutic uses

As shown in Table 01, AI improves speed, accuracy, and efficiency across multiple stages of pharmaceutical research.

3. MACHINE LEARNING AND DEEP LEARNING IN DRUG DESIGN

Machine learning (ML) and deep learning (DL) are important branches of AI widely used in pharmaceutical chemistry. These technologies analyze large datasets and predict molecular behavior using computational algorithms [8].

Machine learning models classify compounds based on physicochemical properties and biological activity. Common ML techniques include support vector machines (SVM), random forest algorithms, decision trees, and Bayesian networks [9]. These methods assist in predicting molecular stability, therapeutic activity, and toxicity.

Deep learning, a subset of machine learning, uses multilayer neural networks to improve prediction accuracy. Deep neural networks can identify hidden relationships among molecular descriptors and biochemical pathways [10]. These models support ligand-based drug discovery and target-specific optimization.

For example, convolutional neural networks (CNNs) and recurrent neural networks (RNNs) are increasingly used to predict protein–ligand interactions and molecular structures. Deep learning also facilitates de novo molecular design by generating chemically feasible compounds with desired therapeutic characteristics [11].




Figure 02: demonstrates the role of machine learning and deep learning models in drug design.

Table 02: Machine Learning Approaches in Pharmaceutical Chemistry

Algorithm	Application	Advantage
Random Forest	Drug activity prediction	High accuracy
Support Vector Machine	Molecular classification	Better prediction
Neural Networks	Pattern recognition	Complex data analysis
Deep Learning	Molecular optimization	High precision

Table 02: Indicates that ML and DL methods improve predictive performance and accelerate pharmaceutical innovation.

4. AI-BASED TARGET IDENTIFICATION AND VALIDATION

Target identification is a crucial stage in pharmaceutical development. AI technologies help identify disease-related genes, proteins, and signaling pathways associated with pathological conditions [12].

Traditional experimental target identification methods are costly and time-intensive. AI-based systems analyze genomic, transcriptomic, and proteomic datasets to identify disease biomarkers more efficiently [13]. Algorithms recognize biological patterns and establish molecular associations with disease progression.

AI-assisted validation also improves confidence in selected therapeutic targets by simulating biological interactions and predicting therapeutic outcomes. Pharmaceutical researchers increasingly utilize AI to

identify novel protein targets in oncology, neurodegenerative disorders, and infectious diseases [14].

The use of AI in target validation enhances drug precision, minimizes experimental errors, and reduces late-stage clinical failures.




Figure 03: illustrates AI-assisted target identification and validation processes in pharmaceutical research.

Table 03: Benefits of AI-Based Target Identification

Parameter	Traditional Method	AI-Based Method
Time Consumption	High	Low
Accuracy	Moderate	High
Cost	Expensive	Reduced
Biomarker Detection	Limited	Extensive

The findings summarized in Table 03 demonstrate the growing importance of AI in identifying therapeutic targets with improved efficiency.

5. VIRTUAL SCREENING AND MOLECULAR DOCKING

AI-assisted virtual screening accelerates compound identification by evaluating thousands of molecules against therapeutic targets. Molecular docking predicts

ligand–protein binding affinity and drug efficacy [15]. AI improves prediction accuracy and reduces laboratory screening costs. These approaches have become important in anticancer and antiviral drug discovery.

6. GENERATIVE AI IN DE NOVO DRUG DESIGN

Generative AI models create novel molecular structures with desirable pharmacological properties [16]. Algorithms such as generative adversarial networks (GANs) and reinforcement learning design molecules with improved selectivity, efficacy, and safety. This strategy minimizes development time and increases molecular diversity.

7. PREDICTIVE TOXICOLOGY AND ADMET MODELING

AI-based ADMET prediction evaluates absorption, distribution, metabolism, excretion, and toxicity profiles during early drug development [17]. Predictive toxicology helps eliminate harmful compounds before clinical trials, reducing failure rates and development expenses.

Table 04: AI Applications in Drug Development

Stage	AI Contribution
Target Identification	Disease biomarker analysis
Virtual Screening	Rapid compound screening
Drug Optimization	Structural refinement
Toxicity Prediction	Safety assessment

As shown in Table 04, AI enhances precision throughout pharmaceutical development.

8. GREEN CHEMISTRY IN PHARMACEUTICAL SYNTHESIS

Green chemistry focuses on eco-friendly pharmaceutical production through reduced waste, safer solvents, and energy-efficient synthesis [18]. Sustainable methods lower environmental toxicity and improve industrial safety.

9. GREEN SOLVENTS AND SUSTAINABLE CATALYSIS

Eco-friendly solvents such as water, ionic liquids, and supercritical fluids reduce hazardous chemical usage [19]. Sustainable catalysts improve reaction efficiency and product yield with minimal waste generation.

10. MICROWAVE-ASSISTED AND ULTRASOUND-ASSISTED SYNTHESIS

Microwave-assisted synthesis accelerates reaction rates and minimizes solvent use, while ultrasound-assisted synthesis improves reaction efficiency under mild conditions [20]. These techniques support sustainable pharmaceutical production.

11. BIOCATALYSIS AND ENZYME-MEDIATED SYNTHESIS

Biocatalysis employs enzymes for selective and environmentally safe synthesis [21]. Enzyme-mediated reactions improve product specificity and reduce harmful by-products in pharmaceutical manufacturing.

12. CONTINUOUS FLOW CHEMISTRY

Continuous flow systems enhance reaction control, safety, and scalability while minimizing waste generation [22]. This approach is increasingly adopted in pharmaceutical industries for green manufacturing.




Figure 04: Integration of AI and Green Pharmaceutical Chemistry

13. INTEGRATION OF AI WITH GREEN SYNTHESIS

The integration of AI with green chemistry optimizes reaction pathways, predicts sustainable synthesis methods, and reduces chemical waste [23]. AI-based predictive modeling improves energy efficiency and process optimization in pharmaceutical industries.

14. CHALLENGES AND LIMITATIONS

Despite advantages, AI implementation faces challenges including poor-quality datasets, computational expenses, algorithm transparency, and regulatory concerns [24]. Green synthesis approaches may also face scalability and industrial adaptation limitations.

15. FUTURE PROSPECTS

Future pharmaceutical chemistry is expected to increasingly adopt AI-supported sustainable drug development. Advanced predictive analytics and environmentally friendly synthesis technologies may accelerate safer and cost-effective therapeutic innovation [25].

16. CONCLUSION

AI-driven drug design and green synthesis strategies are reshaping pharmaceutical chemistry by improving efficiency, sustainability, and therapeutic precision. AI accelerates target identification, molecular screening,

and toxicity prediction, while green chemistry minimizes environmental impact through safer and energy-efficient synthesis methods. The integration of these technologies offers significant opportunities for sustainable drug development. However, challenges related to regulation, data quality, and industrial scalability require further attention. Future advancements in AI-assisted green pharmaceutical manufacturing are expected to transform modern therapeutic innovation.

17. REFERENCES

- World Health Organization. *Global benchmarking tools for evaluation of national regulatory systems*. Geneva: WHO; 2023.
- Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discov Today*. 2019;24(3):773-780.
- Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18(6):463-477.
- Schneider G. Automating drug discovery. *Nat Rev Drug Discov*. 2018;17(2):97-113.
- Jing Y, Bian Y, Hu Z, Wang L, Xie X. Deep learning for drug design: an artificial intelligence paradigm for drug discovery. *Nat Rev Drug Discov*. 2023;22(5):337-357.
- Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov*. 2010;9(3):203-214.
- Zhavoronkov A, Aladinskiy VA, Zhebrak A, et al. Potential COVID-2019 therapeutics identified using artificial intelligence. *Mol Pharm*. 2020;17(11):3904-3908.
- Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. *Drug Discov Today*. 2018;23(6):1241-1250.
- Ekins S. Exploiting machine learning for end-to-end drug discovery and development. *Nat Mater*. 2019;18(5):435-441.
- Walters WP, Murcko MA. Prediction of drug-likeness. *Adv Drug Deliv Rev*. 2002;54(3):255-271. (Corrected year and bibliographic details)
- Segler MHS, Kogej T, Tyrchan C, Waller MP. Generating focused molecule libraries for drug discovery using recurrent neural networks. *ACS Cent Sci*. 2018;4(1):120-131.
- Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. *Cell*. 2020;180(4):688-702.e13.
- Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. *Br J Pharmacol*. 2011;162(6):1239-1249.
- Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. *Pharmacol Rev*. 2014;66(1):334-395.
- Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery. *Curr Top Med Chem*. 2014;14(16):1923-1938.
- Elton DC, Boukouvalas Z, Fuge MD, Chung PW. Deep learning for molecular design-a review of the state of the art. *Mol Syst Des Eng*. 2019;4(4):828-849.
- Raies AB, Bajorath J. Predicting ADMET properties of compounds. *WIREs Comput Mol Sci*. 2016;6(6):679-690.
- Anastas PT, Warner JC. *Green chemistry: theory and practice*. New York: Oxford University Press; 1998.
- Clarke CJ, Tu W-C, Levers O, Bröhl A, Hallett JP. Green and sustainable solvents in chemical processes. *Chem Rev*. 2018;118(2):747-800.
- Kappe CO. Controlled microwave heating in modern organic synthesis. *Angew Chem Int Ed Engl*. 2004;43(46):6250-6284.
- Sheldon RA, Woodley JM. Role of biocatalysis in sustainable chemistry. *Chem Rev*. 2018;118(2):801-838.
- Plutschack MB, Pieber B, Gilmore K, Seeberger PH. The hitchhiker's guide to flow chemistry. *Chem Rev*. 2017;117(18):11796-11893.
- Butler KT, Davies DW, Cartwright H, Isayev O, Walsh A. Machine learning for molecular and materials science. *Nature*. 2018;559(7715):547-555.
- Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: opportunities and challenges. *ACS Med Chem Lett*. 2021;12(4):581-589.
- Lavecchia A. Machine-learning approaches in drug discovery: methods and applications. *Drug Discov Today*. 2015;20(3):318-331.